Aptinyx is a clinical-stage biotechnology company developing novel small molecules targeting the N-methyl-D-aspartate receptors, which are vital to normal and effective brain and nervous system functions, for the treatment of CNS disorders.
In order to optimize our website for you and to be able to continuously improve it, we use cookies. By continuing to use the website, you agree to the use of cookies. Further information on cookies can be found in our Privacy Policy.
